Use of a human-centered design approach to adapt a nurse-led cardiovascular disease prevention intervention in HIV clinics.
Anti-HIV Agents
/ adverse effects
Cardiovascular Diseases
/ diagnosis
Delivery of Health Care, Integrated
Feasibility Studies
Female
HIV Infections
/ diagnosis
HIV Long-Term Survivors
Health Status
Humans
Leadership
Male
Middle Aged
North Carolina
Nurse's Role
Ohio
Patient Acceptance of Health Care
Patient-Centered Care
Preventive Health Services
Stakeholder Participation
Treatment Outcome
Viral Load
CVD prevention
CVD-HIV integration
Human-centered design
Nurse-led intervention
Journal
Progress in cardiovascular diseases
ISSN: 1873-1740
Titre abrégé: Prog Cardiovasc Dis
Pays: United States
ID NLM: 0376442
Informations de publication
Date de publication:
Historique:
received:
18
02
2020
accepted:
18
02
2020
pubmed:
25
2
2020
medline:
23
6
2020
entrez:
25
2
2020
Statut:
ppublish
Résumé
Stakeholder-informed strategies addressing cardiovascular disease (CVD) burden among people living with HIV (PWH) are needed within healthcare settings. This study provides an assessment of how human-centered design (HCD) guided the adaptation of a nurse-led intervention to reduce CVD risk among PWH. Using a HCD approach, research staff guided two multidisciplinary "design teams" in Ohio and North Carolina, with each having five HCD meetings. We conducted acceptability and feasibility testing. Six core recommendations were produced by two design teams of key stakeholders and further developed after the acceptability and feasibility testing to produce a final list of 14 actionable areas of adaptation. Acceptability and feasibility testing revealed areas for adaptation, e.g. patient preferences for communication and the benefit of additional staff to support patient follow-up. In conclusion, along with acceptability and feasibility testing, HCD led to the production of 14 key recommendations to enhance the effectiveness and scalability of an integrated HIV/CVD intervention.
Identifiants
pubmed: 32092444
pii: S0033-0620(20)30053-0
doi: 10.1016/j.pcad.2020.02.013
pmc: PMC7237285
mid: NIHMS1569785
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-100Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL123341
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL137611
Pays : United States
Organisme : HSRD VA
ID : IK6 HX003161
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL142099
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI064518
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The author has no conflict of interest to declare.
Références
JAMA. 2020 Jan 7;323(1):19-20
pubmed: 31825458
J Assoc Nurses AIDS Care. 2014 Jan-Feb;25(1):60-9
pubmed: 24070645
Digit Health. 2019 Feb 06;5:2055207619827716
pubmed: 30792877
Am Heart J. 2019 Oct;216:91-101
pubmed: 31419622
Implement Sci. 2019 Jun 6;14(1):58
pubmed: 31171014
AIDS. 2018 Jul 1;32 Suppl 1:S107-S113
pubmed: 29952796
Patient Educ Couns. 2019 Mar;102(3):503-510
pubmed: 30446358
JMIR Hum Factors. 2018 Dec 19;5(4):e11048
pubmed: 30567688
PLoS One. 2014 Aug 29;9(8):e103205
pubmed: 25170939
PLoS One. 2017 Nov 1;12(11):e0186744
pubmed: 29091935
Matern Child Health J. 2015 Dec;19(12):2552-9
pubmed: 26197732
Transl Behav Med. 2019 Jan 1;9(1):1-10
pubmed: 29346635
Transl Behav Med. 2017 Sep;7(3):389-392
pubmed: 28884305
Am J Prev Med. 2015 Apr;48(4):472-9
pubmed: 25700655
Pilot Feasibility Stud. 2019 Feb 20;5:28
pubmed: 30820339
Am J Prev Med. 2016 Oct;51(4 Suppl 2):S124-31
pubmed: 27371105
AIDS. 2018 Jul 1;32 Suppl 1:S1-S3
pubmed: 29952785
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426